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Skeletal muscle apoptosis and autophagy are catabolic processes
that contribute to muscle atrophy during aging, disease, and fol-
lowing muscle injury. In this article, we present data on skeletal
muscle apoptosis, autophagy, and morphology in C57BL/6 mice
following doxorubicin administration. More speciﬁcally, time-
course data on caspase-3, caspase-8, caspase-9, calpain, and
cathepsin activity are presented, along with data on ATG7, p62,
LC3-I, and LC3-II protein expression. Data on skeletal muscle
reactive oxygen species (ROS) production, muscle morphology, as
well as body and muscle weights are also presented.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
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T.L. Campbell, J. Quadrilatero / Data in Brief 7 (2016) 786–793 787xperimental
factorsC57BL/6 mice received a single intraperitoneal injection of doxorubicin and were
sacriﬁced at given time points.xperimental
featuresC57BL/6 mice were sacriﬁced prior to (i.e. day 0) and 1, 3, 5, 7, and 9 days after a
single intraperitoneal injection of doxorubicin. Different skeletal muscles were
isolated and weighed, and samples prepared for microscopy, spectroﬂuorometric
assays, and immunoblotting.ata source
locationUniversity of Waterloo, Waterloo, Ontario, Canadaata accessibility All data are provided with this articleD
Value of the data
● Provides a simultaneous assessment of skeletal muscle apoptosis, autophagy, and morphology in
response to systemic doxorubicin administration.
● Provides time-course data on skeletal muscle morphology and degradative processes following
doxorubicin administration.
● Valuable for researchers interested in the relationship between apoptosis and autophagy in skeletal
muscle.
● Help other researchers determine the utility of doxorubicin as a myotoxic agent.1. Data
Here we present data regarding the ability of systemic doxorubicin administration to induce
skeletal muscle atrophy and morphological changes. Given that apoptosis and autophagy can impact
muscle morphology and wasting [1,2] we also provide data on apoptotic and autophagic signaling in
several muscles following doxorubicin administration.
1.1. Body and muscle weights following doxorubicin administration
There was a trend (p¼0.07) towards a signiﬁcant decrease in body weight after doxorubicin
administration (Fig. 1A). There were no statistically signiﬁcant differences in soleus, plantaris, or
gastrocnemius weights with doxorubicin. Further, there were no signiﬁcant differences in muscle
weights when normalized to body weight for both the soleus (Fig. 1B) or plantaris (Fig. 1C) following
doxorubicin administration. However, post hoc analysis revealed a signiﬁcant (po0.05) difference in
gastrocnemius weight when normalized to body weight at day 1 compared to day 9 (Fig. 1D).
1.2. Apoptotic enzyme activity and reactive oxygen species (ROS) generation following doxorubicin
treatment
There were no statistically signiﬁcant differences in caspase-3 (Fig. 2A), caspase-8 (Fig. 2B),
caspase-9 (Fig. 2C), or calpain (Fig. 2D) activity, nor ROS production (Fig. 2E) in mixed gastrocnemius
between any of the measured time points (Day 0, 1, 3, 5, 7, and 9) following doxorubicin
administration.
1.3. Autophagic protein expression and cathepsin activity after doxorubicin administration
There were no differences in ATG7 (Fig. 3A and C) or p62 (Fig. 3A and D) protein between any of
the measured time points in the soleus following doxorubicin administration. Post hoc analysis
revealed a signiﬁcant (po0.05) increase in LC3-I protein in soleus on day 3 post-doxorubicin injection
compared to day 1 (Fig. 3A and E). There was no statistically signiﬁcant difference in LC3-II protein
(Fig. 3A and F), nor the LC3-II/LC3-I protein ratio (Fig. 3A and G) in the soleus at any time point
following doxorubicin administration. There were no signiﬁcant differences in ATG7 protein (Fig. 3B
Fig. 1. Body weight (A), as well as soleus (B), plantaris (C), and gastrocnemius (D) muscle weights normalized to body weight
(BW) prior to (day 0) and following (day 1, 3, 5, 7, 9) doxorubicin administration (n¼3). *po0.05, signiﬁcant difference
compared to day 9.
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protein (Fig. 3B and D) was signiﬁcantly (po0.05) higher on day 3 compared to day 0, 1, 5, and 9.
There were no signiﬁcant differences in LC3-I protein (Fig. 3B and E), LC3-II protein (Fig. 3B and F), or
the LC3-II/LC3-I protein ratio (Fig. 3B and G) in the plantaris at any time point following doxorubicin
administration. Finally, there were no statistically signiﬁcant differences in cathepsin activity between
time points in mixed gastrocnemius following doxorubicin administration (Fig. 3H).
1.4. Qualitative analysis of muscle morphology after doxorubicin exposure
Visual inspection of soleus and plantaris cross-sections stained with hematoxylin & eosin (H & E)
showed no obvious signs of muscle damage or changes in muscle morphology at any time point after
doxorubicin administration (Fig. 4). Additionally, there were no apparent increases in the presence of
centralized nuclei after doxorubicin administration.2. Experimental design, materials and methods
2.1. Experimental design
Male C57BL/6 mice between the ages of 13–17 weeks were sacriﬁced by cervical dislocation prior
to (i.e. day 0) and 1, 3, 5, 7, or 9 days (n¼3 for each time point) following a single intraperitoneal
injection of doxorubicin at a concentration of 20 mg/kg body weight. This dose has previously been
Fig. 2. Caspase-3 (A), caspase-8 (B), caspase-9 (C), and calpain (D) activity, as well as ROS generation (E) data from mixed
gastrocnemius prior to (day 0) and following (day 1, 3, 5, 7, 9) doxorubicin administration (n¼3).
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muscle at 24 h or 48 h following administration [3–6].2.2. Muscle extraction and sample preparation
After sacriﬁce, the soleus, plantaris, and gastrocnemius (mixed) were extracted from both hin-
dlimbs. A sample of the entire circumference from the middle portion of one soleus and one plantaris
was mounted in Optimal Cutting Temperature (OCT) compound and frozen in liquid nitrogen-cooled
Fig. 3. Representative immunoblots from soleus (A) and plantaris (B) of ATG7, p62, LC3-I, and LC3-II protein expression prior to
(day 0) and following (day 1, 3, 5, 7, 9) doxorubicin administration. Quantitative analysis of ATG7 (C), p62 (D), LC3-I (E), and
LC3-II (F) protein, as well as the LC3-II/LC3-I protein ratio (G) in soleus and plantaris before and after doxorubicin treatment
(n¼3). Quantitative analysis of cathepsin activity (H) from mixed gastrocnemius prior to and following doxorubicin injection
(n¼3). *po0.05, signiﬁcant difference compared to day 0, 1, 5, and 9. #po0.05, signiﬁcant difference compared to day 1.
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Fig. 4. Representative H & E stained muscle cross-sections from soleus and plantaris muscle prior to (day 0) and following (day
1, 3, 5, 7, 9) doxorubicin administration. Scale bar¼100 mm.
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dually frozen in liquid nitrogen and stored at 80 °C.
Soleus and plantaris muscle samples used for immunoblotting were homogenized in ice-cold lysis buffer
(20 mM HEPES, 10 mM NaCl, 1.5 mM MgCl2, 1 mM DTT, 20% glycerol and 0.1% Triton X-100; pH 7.4) con-
taining protease inhibitors (Complete Cocktail; Roche Diagnostics). Mixed gastrocnemius muscle samples
used for caspase, calpain, and cathepsin activity assays were homogenized in lysis buffer but without
protease inhibitors. Homogenates were then centrifuged for 10 min at 1000g at 4 °C and supernatants
collected and stored at 80 °C. Mixed gastrocnemius samples for ROS assays were homogenized in ice-cold
buffer (250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT; pH 7.4) con-
taining protease inhibitors (Complete Cocktail; Roche Diagnostics). Total protein concentrations were
determined by the BCA protein assay.
2.3. Proteolytic enzyme activity
Caspase-3, -8, and -9 activity in mixed gastrocnemius homogenates were assessed using the
substrates Ac-DEVD-AMC (Enzo Life Sciences), Ac-IETD-AMC (Sigma-Aldrich), and Ac-LEHD-AMC
(Enzo Life Sciences), respectively, as previously performed [7]. Calpain activity was measured in
mixed gastrocnemius homogenates using Suc-LLVY-AMC (Enzo Life Sciences) either with or without
the calpain inhibitor Z-LL-CHO (Enzo Life Sciences). Calpain activity was calculated as the difference
between the average ﬂuorescence of wells with and without the inhibitor [7]. Cathepsin activity was
determined in mixed gastrocnemius homogenates using z-FR-AFC (Enzo Life Sciences) as previously
described [8]. Fluorescence for all enzymes was determined using a SPECTRAmax Gemini XS
microplate spectroﬂuorometer (Molecular Devices), then normalized to total protein content, and
expressed as arbitrary units per milligram of protein.
2.4. Reactive oxygen species generation
Reactive oxygen species (ROS) generation was assessed in mixed gastrocnemius using
dichloroﬂuorescein-diacetate (DCFH-DA) (Life Technologies) [9]. Fluorescence was determined using
a SPECTRAmax Gemini XS microplate spectroﬂuorometer (Molecular Devices). Fluorescence was
normalized to total protein content and presented as arbitrary units per milligram of protein.
2.5. Immunoblotting analyses
Immunoblotting was performed using soleus and plantaris muscle samples as previously descri-
bed [10]. Brieﬂy, equal amounts of protein were loaded into 12% SDS-PAGE gels, separated by elec-
trophoresis, and transferred onto PVDF membranes (BioRad). Blocked membranes were incubated in
primary antibody against ATG7 (Cell Signaling Technology), LC3B (Cell Signaling Technology), and p62
(Progen Biotechnik) overnight at 4 °C, washed, and incubated with the appropriate horseradish
peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology) for 1 h at room temperature.
Protein bands were imaged using Clarity Western ECL Substrate (BioRad) and the ChemiGenius 2 Bio-
Imaging System (Syngene). Membranes were also stained with Ponceau S (Sigma-Aldrich) to verify
equal protein loading and quality of protein transfer.
2.6. Histochemical analyses
Soleus and plantaris muscle cross-sections mounted on microscope slides were ﬁrst stained with
hematoxylin for 30 s, after which excess hematoxylin was quickly removed, and slides washed in
distilled water. Cross-sections were then stained with eosin for 90 s, after which excess eosin was
quickly removed. Slides were then treated with graded ethanol incubations, a xylene clearing step,
and ﬁnally coverslips mounted with permount.
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All quantitative data was analyzed using 1-way ANOVAs and Tukey's post hoc tests, with po0.05
being considered statistically signiﬁcant.Acknowledgments
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